Dong Chao-Hui, Wang Zhang-Min, Chen Si-Yu
Department of Cardio-Pulmonary Rehabilitation, The Affiliated Rehabilitation Hospital of Chongqing Medical University, China.
Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Clin Biochem. 2018 Feb;52:131-136. doi: 10.1016/j.clinbiochem.2017.11.008. Epub 2017 Nov 11.
Neutrophil to lymphocyte ratio (NLR) might be associated with the mortality or major adverse cardiac events (MACEs) in acute coronary syndrome (ACS) patients. We performed a meta-analysis to evaluate the correlation between NLR and mortality/MACEs in ACS.
We assessed clinical trials through Pubmed, EMBASE, the Cochrane Library and Web of science in investigating the association between NLR and mortality/MACEs in ACS patients up to August 15, 2017. The primary outcome was mortality or recurrent MACEs.
In total, 8 studies of 9406 patients were included in the systematic and meta-analysis. Our analysis indicated that elevated pretreatment NLR was a poor prognostic marker for patients with recent ACS in predicting medium to long-term mortality/MACEs (OR 1.26, 95%CI 1.13-1.41). And the analysis indicated that higher pretreatment NLR value was associated with higher in-hospital mortality in ACS patients (OR 6.39, 95%CI 1.49-27.38, p<0.001). The NLR value of 5.0 maybe a cut-off value for ACS risk.
In patients with a recent ACS, an elevated pretreatment NLR value is effective in predicting the risk of mortality/MACEs.
中性粒细胞与淋巴细胞比值（NLR）可能与急性冠状动脉综合征（ACS）患者的死亡率或主要不良心脏事件（MACE）相关。我们进行了一项荟萃分析，以评估NLR与ACS患者死亡率/MACE之间的相关性。
我们通过PubMed、EMBASE、Cochrane图书馆和科学网评估临床试验，以调查截至2017年8月15日NLR与ACS患者死亡率/MACE之间的关联。主要结局是死亡率或复发性MACE。
系统评价和荟萃分析共纳入8项研究，涉及9406例患者。我们的分析表明，在预测中长期死亡率/MACE方面，ACS患者治疗前NLR升高是不良预后指标（OR 1.26，95%CI 1.13-1.41）。分析还表明，ACS患者治疗前NLR值越高，住院死亡率越高（OR 6.39，95%CI 1.49-27.38，p<0.001）。NLR值5.0可能是ACS风险的临界值。
在近期ACS患者中，治疗前NLR值升高可有效预测死亡率/MACE风险。
